CSL's Annual R&D Investor Briefing 2020

For immediate release 20 October 2020 CSL’s Annual R&D Investor Briefing 2020

CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL will hold its annual Research and Development briefing today; the presentation is attached for the information of investors.

Amongst other achievements, CSL is pleased to highlight the following :

• Its work across a number of programs across our R&D platforms to prevent and treat COVID-19.

• CSL’s AEGIS-II Phase 3 study of CSL112 (ApoA-1) for treatment of acute coronary syndrome has now resumed following a COVID related pause. More than 10,000 people have been enrolled to date.

• Results from Phase 2 clinical trials for Garadacimab, a treatment in hereditary angioedema (HAE), met its primary end points with a statistically significant reduction in HAE attacks.

• US Food & Drug Administration approval for an expanded label indication for Haegarda, to now include patients of 6 years and older.

• The aquisition of Clazakizumab (CSL300), an anti-interleukin-6 monoclonal antibody in the IMAGINE Phase 3 trial for the treatment of chronic active antibody-mediated rejection, the leading cause of long-term rejection in kidney transplant recipients.

Shareholders can access the briefing through CSL’s website at CSL.com

Approved for Release

Fiona Mead Company Secretary

For further information, please contact: Investors: Media: Mark Dehring Christina Hickie Head of Investor Relations Senior Manager, Communications Phone: +61 393 893 407 Phone: +61 429 609 762 Email: [email protected] Email: [email protected]

R&D Investor Briefing 2020

20th October 2020 Forward looking statements The information in this presentation is current as of the date of this presentation, and includes forward looking statements about CSL Limited and its related bodies corporate’s (CSL) financial results and estimates, business prospects and product candidates in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of R&D activities, decisions by regulatory authorities regarding product Legal registration and label claims; competitive developments; marketing challenges; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation Notice or government investigations, and CSL’s ability to secure intellectual property protection. The statements made in this presentation should not be construed as an offer to sell, or solicitation of an offer to buy, any securities of CSL. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL), including in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which such statements are based. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL does not undertake to disseminate updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

2 Introduction William Mezzanotte MD

Executive Vice President, Head of Research and Development and CMO

CSL Behring

3 Agenda

Topic Presenter Welcome Mark Dehring Introduction and Highlights Bill Mezzanotte

Research - Protein Therapies, Gene Therapies & Vaccines Andrew Nash Immunology Highlights & COVID-19 Response Mittie Doyle Commercial Bill Campbell Transplant Highlights Laurie Lee Summary Bill Mezzanotte Q&A Panel Close

4 Global Research and Development Footprint

King of Prussia US Amsterdam Netherlands LiverpoolUK

Kankakee US Marburg Germany London UK Tokyo Japan Cambridge US Siena Italy Pasadena US BernSwitzerland Summit US Wuhan China Shanghai China Holly SpringsUS

 CSL Behring  Seqirus Melbourne Australia > 1,700 scientists globally

5 Key Global Research Partnerships for Early Innovation Access

6 Commitment to Research and Development

922 832 New Product Development activities focus on innovative new 667 702 therapies for life-threatening 614 diseases

Market Development strategies seek to bring therapies to new markets and new indications

Life Cycle Management ensures continuous improvement of existing products

15-16 16-17 17-18 18-19 19-20 Includes R&D for CSL Behring and Seqirus. Investment reported in US$ millions

R&D investment ~10-11% global revenue

7 Focus Through Our Therapeutic Areas and Platforms

8 R&D Portfolio – December 2019

Registration/ Research Pre-Clinical Phase I Phase II Phase III Post-Registration

DiscoveryProjects CSL510 CSL730 Garadacimab HIZENTRA® PRIVIGEN® Modified Fibrinogen rFc Multimer Anti-FXIIa (HAE) mAb (DM) (PID) JP

DiscoveryProjects CSL787 CSL324 HIZENTRA® CSL112 CSL830 Nebulised Ig Anti-G-CSFR mAb (SSc) ApoA-1 (ACS) C1-INH Subcut EU

DiscoveryProjects aQIVc CSL200 PRIVIGEN® Clazakizumab PRIVIGEN® Adjuvanted Cell Culture CAL-H (SCD) (SSc) Anti-IL-6 (AMR) mAb (CIDP) US, JP Influenza Vaccine DiscoveryProjects CSL889 HAEGARDA® CSL842 HIZENTRA® P. Gingivalis Hemopexin (SCD) Japan C1-INH (rAMR) (CIDP) US, JP Periodontal Disease DiscoveryProjects Garadacimab CSL630 CSL964 AAT HAEGARDA® Anti-FXIIa (Thrombosis) pdFVIII Ruide (GvHD Treatment) US

CSL311 Mavrilimumab CSL964 AAT IDELVION® Anti-Beta Common mAb Anti-GM-CSFR mAb (GvHD Prevention)

CSL346 FLUCELVAX® QIV AFSTYLA® Anti-VEGF-B mAb 6M+

CSL334 / ASLAN004 KCENTRA® (Anti-IL-13R) Japan

ZEMAIRA® / RESPREEZA® AAT

AFLURIA® QIV 6M+ US, AU

FLUAD® QIV 65yrs+ US,EU,CA

AUDENZ™ Adjuvanted Monovalent Immunology Haematology Respiratory Cardiovascular & Metabolic Influenza A (H5N1) Vaccine Transplant Influenza Vaccines Outlicensed Programs Partnered Projects

9 R&D Portfolio Highlights - FY20

Immunology Respiratory Acquisitions & • HIZENTRA® Phase III DM study initiated Alliances • CSL311 (Anti-Beta Common) Phase I study in • Alliance with Seattle Children’s Research HAEGARDA® Phase III HAE study in Japan mild asthmatic patients initiated • Institute to develop WAS & XLA stem cell gene initiated therapies for PID • HAEGARDA® paediatric approval in US Cardiovascular and • Agreed to acquire exclusive global license rights to AMT-061 (EtranaDez) for haemophilia B* • PRIVIGEN® approved for PID, SID & CIDP in Metabolic Japan • Acquisition of Vitaeris Inc. and Clazakizumab • CSL112 (ApoA-1) Phase III study (AEGIS-II) >9500 • Garadacimab (Anti-FXIIa) Phase II HAE study patients recruited results presented at EAACI Congress; FDA * Transaction with uniQure is subject to customary regulatory granted orphan drug designation (ODD) • CSL112 (ApoA-1) AEGIS-II first futility analysis clearances before closing conducted; trial to continue as planned • FDA granted HIZENTRA® ODD for CIDP

Haematology Transplant Influenza Vaccines

• AAT for prevention of GvHD Phase III study • CSL200 (Gene Therapy) in SCD Phase I study • Adjuvanted quadrivalent influenza vaccine, enrolment into Cohort 2 completed initiated FLUAD® TETRA, approval in EU and FLUAD® QUADRIVALENT in US • FDA granted AAT ODD for GvHD treatment & • FDA granted CSL200 fast track designation prevention • US FDA approval of AUDENZ™ - adjuvanted, • CSL889 (Hemopexin) Phase I SCD study initiated cell-based influenza A (H5N1) pandemic vaccine • Clazakizumab AMR study initiated • CSL889 (Hemopexin) ODD approved in EU & US • aQIVc (cell antigen + MF59®) new product FDA granted Clazakizumab ODD and fast track for SCD • development commenced designation for CABMR

10 Key Past Launches from R&D Portfolio 2015 2016 2017 2018 2019 2020 HIZENTRA® PRIVIGEN® CIDP (US) ® CIDP (JP) Ig IsoLo® HIZENTRA PRIVIGEN® Immunology CIDP PID/SID (JP) ® HAEGARDA® (US) PRIVIGEN CIDP (JP)

IDELVION® IDELVION® 21-Day (EU)^ Haematology IDELVION® AFSTYLA® 21-Day (JP)

Respiratory RESPREEZA® (EU)

® FLUCELVAX ® AFLURIA® QIV FLUAD® (UK) FLUAD QIV (US) QIV 9yrs+ (EU, CA) Influenza ® FLUAD® QIV (EU) FLUCELVAX ® Vaccines FLUCELVAX® AFLURIA QIV 6M+ FLUAD® (US) QIV (US) (AU)

Timelines shown by calendar year ^ Expanded label for dosing every 21 days for patients ≥12 years in age, depending on individual patient and efficacy (and jurisdiction) 11 Notable Regional Regulatory Action 1 July 2019 – 1 October 2020

CSL889 65yrs+ 6mo+ (treatment SCD*) Garadacimab (Bk-AE*) 65yrs+ CSL889 (treatment SCD*) 21d dosing CSL964 (prevention GvHD***) Human Albumin 20% CSL964 (treatment GvHD***) Extension to register in 1) 21d dosing^ Clazakizumab (CABMR****) Paediatric Indication 11 countries 2) 3500 IU

1) PID/SID Indication 2) CIDP Indication

CIDP Indication

CIDP Indication 1) 21d dosing 2) 3500 IU For MMN/SID

CIDP Indication

2000 IU/3000 IU CIDP Indication

1) 21d dosing 2) 3500 IU New Initial Marketing CIDP Indication Authorization Approvals New Line Extensions/ CIDP Indication Indications Approvals 9yrs+ Orphan Drug Designation

On-going Activities * Bk-AE: bradykinin-mediated angioedema ** SCD: Sickle Cell Disease Expanded label for Expanded label for dosing Labeling update for *** GvHD: Graft-versus-Host Disease enhanced administration every 21 days in patients ≥12 expanded populations **** CABMR: Chronic Antibody-Mediated Rejection parameters years of age ^ Every 21 days in patients ≥12 years of age, depending on individual patient and efficacy (and jurisdiction) 12 R&D Portfolio Progression in 2020

Pre-Clinical/ Registration/ Phase I Phase II Phase III Post-Registration

CSL888 CSL346 Garadacimab PRIVIGEN® Haptoglobin (SAH) Anti-VEGF-B mAb Anti-FXIIa mAb(HAE) (PID) JP

® CSL787 Garadacimab HAEGARDA IDELVION® Nebulised Ig Anti-FXIIa mAb (ARDS) Japan rFIX-FP (HaemB) 21d dosing CSL311 aQIVc Anti-Beta Common mAb MF59® plus FLUCELVAX® QIV 9yrs+ FLUCELVAX® antigen AU CSL040 Novel Complement FLUAD® QIV 65yrs+ Inhibitor EU, US

SA-mRNA Influenza AUDENZ™ Vaccine Adjuvanted Monovalent Influenza A (H5N1) Vaccine

Calendar Year 2020

Immunology Haematology Respiratory Cardiovascular & Metabolic

Transplant Influenza Vaccines COVID

13 CSL112 ApoA-1

• All countries and sites reactivated CSL112 particles • Japan now active and enrolling well

st • 1 futility analysis in 2020 passed ABCA1 transporter Intracellular cholesterol

1° Endpoint : MACE MACE Follow Up D90 D180 D365

>17,000 AMI subjects 6g CSL112 ≥18yrs of age with Acute Screening Randomisation Coronary Syndrome Placebo

AMI – Acute Myocardial Infarction MACE - major adverse cardiac events 14 R&D Portfolio – October 2020

Registration/ Research Pre-Clinical Phase I Phase II Phase III Post-Registration

Gene Therapy CSL888 CSL324 HIZENTRA® HIZENTRA® PRIVIGEN® Treatments Haptoglobin (SAH) Anti-G-CSFR mAb (HS) (SSc) (DM) (PID) JP PID CSL510 CSL730 CSL630 HAEGARDA® IDELVION® DiscoveryProjects Modified Fibrinogen rFc Multimer pdFVIII Ruide Japan rFIX-FP (HaemB)

CSL040 CSL889 CSL346 Garadacimab AFSTYLA® DiscoveryProjects Novel Complement Hemopexin(SCD) Anti-VEGF-B mAb Anti-FXIIa mAb(HAE) rFVIII (HaemA) Inhibitor (DKD) CSL200 EtranaDez* ZEMAIRA®/RESPREEZA® DiscoveryProjects SA-mRNA Influenza CAL-H (SCD) Garadacimab Etranacogene Alpha1-Proteinase Vaccine Anti-FXIIa mAb(ILD/IPF) dezaparvovec Inhibitor CSL787 DiscoveryProjects LASN01 Nebulised Ig Garadacimab KCENTRA® AFLURIA® QUAD Anti-IL-11R Anti-FXIIa mAb(ARDS) 4F-PCC (Trauma) Egg-based Influenza CSL311 Vaccine DiscoveryProjects P. Gingivalis Anti-Beta Common mAb Adjuvanted Cell Culture CSL112 (Periodontal Disease) Influenza Vaccine ApoA-1 (ACS) FLUCELVAX® UQ/CSL V451 (aQIVc) Quadrivalent (aCoV2) Clazakizumab Cell-based Influenza Vaccine Mavrilimumab Anti-IL-6 mAb (AMR) CSL334/ASLAN004 Anti-GM-CSFR mAb FLUAD® Quadrivalent Anti-IL-13R mAb(AD) CSL964 Adjuvanted Influenza Alpha-1Antitrypsin Vaccine (Treatment of GvHD) AUDENZ™ CSL964 Adjuvanted Monovalent Alpha-1Antitrypsin Influenza A (H5N1) Vaccine (Prevention of GvHD)

* Transaction with uniQure is subject to customary regulatory COVID-19 clearances before closing Hyperimmune Therapy

Immunology Haematology Respiratory Cardiovascular & Metabolic Transplant

Influenza Vaccines COVID Outlicensed Programs Partnered Projects

15 Research Protein Therapies Gene Therapies Vaccines Andrew Nash PhD

Senior Vice President, Research and CSO

CSL Behring

16 CSL Research

• Global team exploiting internal and external expertise and 4 drug discovery CSL Behring platforms to deliver innovative CSL Behring Research Bern development opportunities across CSL Research Melbourne Swiss Inst. for Translational & Entrepreneurial Medicine, therapeutic areas Bio21 Institute, University University of Bern of Melbourne • Expertise and track record in plasma and recombinant protein drug discovery, influenza vaccines and building capability in cell and gene therapy CSL Behring • Expertise and depth of talent across 6 TAs CSL Behring Research Marburg Research US Pasadena, KOP

Seqirus Research Boston 17 CSL Behring Research – Sourcing Innovation Research External Innovation Strategy - the competition for innovation Walter and Eliza Hall Institute (WEHI) Bioinformatics Alliance Seattle Children’s Institute Gene Therapy Alliance Strategic Partnerships (universities, Research Acceleration Initiatives MRIs, hospitals) AU, EU, US Global Funding & Source of 48% new external collaborations Research site collaboration FY19-20 CSL has option to exclusively license locations initiatives

Research Pipeline BIO USA Partnering Funding & conference BIO EU collaboration attendance & initiatives Biotechgate sponsorship MRCF/BTF AusBiotech Biotech Biopole Life Sciences Hub partnerships Baselaunch & licensing

Biosana Pharma Elektrofi

18 Growing the Development Portfolio

Platforms Candidates Indications

Plasma PID & SID proteins CSL888 Neutrophilic dermatoses CSL889 ANCA vasculitis CSL787 SLE COPD Asthma CSL312 ARDS CSL324 Pulmonary fibrosis Recombinant CSL346 Thrombotic conditions proteins CSL311 SCD crisis CSL040 Acute bleeding CSL362 Ab graft rejection Delayed graft function GvHD SCD GT Diabetic co-morbidities WAS GT Gene … and others therapy XLA GT

ASLAN004 Atopic dermatitis

LASN01 Fibrosis & oncology

P.ging vaccine Periodontal disease 19 Collaboration Delivers Innovation

Collaboration leads to the Antagonist and agonist discovery that BTN2A1 is required monoclonal antibodies for for the activation of γδ T cells use in autoimmune disease and immuno-oncology

Source: Rigau, M. et al., (2020) Science 367(642) 20 Targeting Complement Regulation

Complement Pathways Potential indications

Chronic Indications, Classical/Lectin Pathway (Anti-C2 mAb)

C1INH

Anti-C2

C1INH Acute Indications, Classical/Lectin Pathway (CSL040)

Cyclic Acute ex vivo Pathway (CSL040) CSL040 solCR1

Anti-C5 Alternative Pathway needing chronic inhibitor (CSL040)

Source: Trouw, L.A. et al., (2017) Nat. Rev. Rheumatol. 13(9);538-547

21 CSL040 Complement Receptor 1 Inhibitor

CR1 Truncation Mutant, rCR1(1392) / CSL040 1152 1310 1481 1763 1534 1605 1028 1504 1540 1908 252 410 959 578 702 509 897 447 860 56

S P LHR-A LHR-B LHR-C LHR-D rCR1(1971) / TP-10 1 42 489 939 1392 1971

S P LHR-A LHR-B LHR-C rCR1(1392) = CSL040

1 42 489 939 1392

Haemolytic complement inhibition assays (human serum) Inhibitor IC50 Classical IC50 Alternative rCR1(1971) 253 pM 2587 pM rCR1(1392) 104 pM 709 pM

rCR1(1392) has 2-3 fold increased potency in vitro as compared to rCR1(1971) / TP-10

22 CSL040 Complement Receptor 1 Inhibitor

Renal Ischemia-reperfusion Injury (IRI) Mouse Model

C57BL/6 Remove right kidney Sacrifice at 24 hrs Inject treatment or vehicle Clamp blood supply to Unclamp i.v. 60 mg/kg CSL040 left kidney for 20' (reperfuse) 1 hr pre-IRI and 3 hr later

• CSL040 inhibits complement activity, leukocyte infiltration and renal damage in IRI model • Pharm/Tox and product development to commence mid-2021

23 Garadacimab

Global leaders in FXII biology – new opportunities for Garadacimab

Auto-activation +FXIIa/β FXI → FXIa FXIIa- FXII FXII Hemostasis

PK → KAL* FXIIa Plasminogen

β Fibroblast/ HK → BK→ BR2 C1qr,s → C1qr,s Plasmin endothelial cell/immune cells Vasodilation Complement Fibrinolysis Mitogenesis activation Inflammation

Beyond Hereditary Angioedema • New opportunities in fibrotic disease, cardiovascular disease, inflammatory disease

* Feedback loops removed for simplicity

24 Garadacimab Plasma FXII levels are higher in IPF patients with progressive disease Pulmonary Fibrosis

Garadacimab reduces fibrosis in the mouse bleomycin model of IPF

Garadacimab from D0 Garadacimab from D5 FXII expression is higher in the IPF lung

Translation to human disease

Phase II to commence H2 2021

IPF – Idiopathic Pulmonary Fibrosis

25 Gene Therapy

AMT-061 (EtranaDez) gene Seattle Children’s Research Direct delivery Cell-based delivery therapy (GT) for the treatment Institute (SCRI) – world leading of Haemophilia B preclinical & clinical experience Treatment or Treatment or missing gene missing gene Patient stem with Lentivirus based GT AAV5 vector encoding FIX cells removed from the body Padua variant The treatment The treatment Alliance consolidates and and cultured gene is added gene is added to extends CSL GT capability May be clinically effective in to a vector such a harmless as an adeno lentivirus patients with pre-existing Abs associated virus Wiskott Aldrich Syndrome (WAS) (AAV) • CSL LVV and Select+ tech. Phase IIb mean FIX activity at 52 …which in turn …which is introduces it to delivered Ph I/II expected to commence H2- weeks 41% the isolated • directly stem cells 2022 to the patient Phase III study in progress by injection XLA The stem cells, Upon deal completion, which is are returned to • SCRI LVV subject to customary regulatory the patient • Ph I/II expected to commence H2- clearances, CSL will have 2022 exclusive global rights to supply

FIX – Factor IX XLA - X-linked agammaglobulinemia 26 LVV – Lentiviral vector Abs - Antibodies Fc Mimetics and Anti-FcRn mAbs

Novel Applications CSL730 Clinical IVIg & SCIg Usage for IgFc Mimetics Development

Immuno- Immuno- replacement modulation Surrogate CSL730 is effective in a model of glomerulonephritis* PID Autoimmune

& SID + - disease + -

CSL / Momenta Responds to Antibody partnership Fcγ mimetics mediated & / or anti-FcRn

Phase I (moved to Ig vs. anti-FcRn subcutaneous Ig supplementation administration) long term persistence vs. immune safety of response suppression * Disease induced by administration and cross-linking of antibodies directed against the kidney glomerular basement membrane

IVIg – Intravenous Immunoglobulin SCIg – Subcutaneous Immunoglobulin 27 CSL – COVID-19 Vaccines

UQ/CSL V451 AZD1222

Partners University of Queensland, AstraZeneca Coalition for Epidemic Preparedness Innovations (CEPI)

Vaccine Format Recombinant virus spike protein Adenovirus vector designed to (molecular clamp technology) express spike protein of COVID-19 formulated with MF59® adjuvant virus in situ

CSL Responsibility Vaccine manufacture, clinical trials, Vaccine manufacture supply

Current Status Ph I ongoing, FSI Ph II/III Dec 2020 Phase III ongoing

FSI – First subject in

28 CSL – COVID-19 Vaccines

Classical Platforms Next-Gen Platforms AZD1222

Candidates in clinical development - 42 7 8 Candidates in pre-clinical development - 151

13 6

UQ/CSL V451 subunit vaccine 2

plus 2 live replicating viral vectors

# In Clinical Development Source: van Riel, D & de Wit, E., (2020) Nature Materials 19; 810-812

29 CSL – Production of UQ/CSL V451

CSL Biotech. Manufacturing Facility, Broadmeadows

2000L Cell Culture Harvest by Depth Drug Drug Product Filling, to be Vaccination Filtration Substance Formulated with MF59®

• Process scaled up and industrialised from Ph I as required • Production, Fill/Finish for Ph II/III underway • Same manufacturing platform technology to be used for AZD1222

30 Immunology & COVID-19 Response Mittie Doyle MD

Vice President, R&D Immunology

CSL Behring

Christal: a nurse living with chronic inflammatory demyelinating polyneuropathy (CIDP)

31 1. FOUNDERS

2. MEMBERS

3. CONTRIBUTORS

4. SUPPORTERS

32 Collaborative Hyperimmune Ig Trial in COVID- 19

Placebo + Remdesivir Screen 500 Randomize Day 1 Patients 1:1 H-Ig + Remdesivir

Anti-COVID-19 Hyperimmune Globulin (H-Ig) will be provided Day 0 Day 7 Day 28 by four manufacturers H-IG Administration Primary Endpoint Secondary Endpoint / End of Study

Phase III enrolling

33 Hyperimmune Program for Australia

• Convalescent plasma collected by the Australian Red Cross Lifeblood

• CSLB has manufactured a clinical batch ready for clinical testing

• A single centre, Phase I, study of the Australian H-Ig product in 24 healthy volunteers

• Leverage global H-Ig data

Phase I to commence H2 2020

34 Potential Benefits of Blocking Factor XIIa in COVID-19

Primary Drivers of ARDS in COVID-19 • Inflammation • Thrombosis Thrombosis Vasodilation, Complement Cytokine • Vascular Permeability vascular permeability activation production

ARDS – Acute Respiratory Distress Syndrome

35 Garadacimab in COVID-19

Garadacimab + Supportive Care

Screening Dosing Primary endpoint Day -2 to 1 1:1 Day 1 Day 2 Day 7 Day 14 Day 21 Day 28 ICF

Placebo + Supportive Care

• Population - 124 patients with severe COVID-19 complications • Primary objective - prevent progression to intra-tracheal intubation or death

Phase II ongoing

36 Garadacimab in HAE: The Vanguard Program

Phase II Study Autosomal dominant genetic condition Phase III Study Design 1 in 10,000 – 50,000 people

Unregulated protein cascade → elevated levels of bradykinin → fluid release into tissues → swelling in specific parts of body Unpredictable onset, severity and attack location, lasts for 2-5 days HAE – Hereditary Angioedema

37 Garadacimab and Factor XIIa in HAE

Garadacimab

Vascular Permeability Angiodema

Landelumab

38 Monthly SC Garadacimab Markedly Reduces Mean HAE Attack Rate (Phase II Study Results) Primary Endpoint

5 4.24 88.68% 98.94% 90.50% (2.74–5.75) 4 Mean Reduction* Mean Reduction* Mean Reduction*

3 Mean Reduction in HAE Attacks per Month vs Placebo 2

1 0.48 0.40 (-0.33–1.29) 0.05 (-0.07–0.88) (-0.06–0.15)

Mean Number HAE of Attacks/Month 0 Garadacimab 75 mg Garadacimab 200 mg Garadacimab 600 mg Placebo q4w (n=9) q4w (n=8) q4w (n=7) q4w (n=8)

Source: Craig, T., (2020) European Academy of Allergy and Clinical Immunology Congress * Mean percentage reduction in HAE attacks vs Placebo 95% CI values are given in brackets 39 HAE - hereditary angioedema; q4w - every 4 weeks; TP1 - Treatment Period 1 VANGUARD Garadacimab Pivotal Phase III Study

Double-Blind, Placebo-Controlled, n=60

Run-in Period

Up~13 to weeks 1 month 1-~132 months weeks 6 months

200 mg Garadacimab N=36 once monthly SC* ≥12 years of age type Baseline attack rate 3:2 1 or 2 HAE ≥1 attack/month N=24 Placebo once monthly SC*

200 mg Garadacimab

Randomization will be stratified by: • Age (≤17 years and >17 years) • Disease severity Phase III to commence H1 2021 * Subjects will receive 400 mg loading dose as first dose (2 × 200 mg)

40 HAE in Japan

No ethnic differences No drugs approved for worldwide* long-term prophylaxis

Prevalence ~1/50,000, Investigating both 2,400 estimated Garadacimab and patients in Japan; HAE HAEGARDA® for long type 1 (85%), type 2 term prophylaxis (15%)

* Source: Zuraw, B. (2010) World Allergy Organ J 3(9 Suppl); S25-8

41 Investigating HAEGARDA® for HAE in Japan

Open-label, single-arm Phase III study in ≥ 8 patients with HAE1+2 • Twice-weekly subcutaneous administration of 60 IU/kg HAEGARDA® • Primary Endpoint: HAE attack rate during treatment vs during Run-in period

Follow-up Screening Run-in period Treatment period period Up to 4 weeks Up to 8 weeks 16 weeks 2 w

End of To confirm the Screening ® study attack rate 60 IU/kg HAEGARDA visit ≥2 attacks in consecutive 4wks ≥1 attack(s) in 1st 2wks

Phase III ongoing

42 Dermatomyositis – a Severe Autoimmune Disease

• Incidence 11 per 1,000,000 • Prevalence rate 14 per 100,000 • Increases with age (peak ages 70-79)*

Presents with proximal weakness, characteristic rash and systemic manifestations

Mortality rate 10-30% (5y), high comorbidity

Current treatment: corticosteroids and azathioprine, other immunosuppressives: no approved disease-modifying anti-rheumatic drugs (DMARDs)

High unmet need for long-term treatments without systemic side effects

* Source: Svensson J, et al., (2017) Clin Exp Rheumatol. 35(3):512-515

43 RECLAIIM Phase III Study of HIZENTRA® in Adults with Dermatomyositis

Weeks 1 to 53 Active DM w/without Steroid rescue if worsening occurs Muscle Weakness

® ® HIZENTRA 0.5 g/kg up A HIZENTRA 0.5 g/kg -

Forced Steroid taper starting at Week 17 if clinically relevant improvement met

Screening ®

Placebo HIZENTRA 0.5 g/kg Telephone Call

B Safety Follow Randomization

Up to 2 months Weeks 1 to 25 Weeks 25 to 53 Week 56

Primary endpoint: TIS responder status

Phase III ongoing

44 Commercial Bill Campbell

Executive Vice President and Chief Commercial Officer

CSL Behring

John, a police officer, and his daughter, Emma, are both living with bleeding disorders.

45 FY20 Highlights Strong underlying demand across the portfolio

Balanced regional & key market growth

New products contributing significantly to growth Sales of $7.7Bn; 1 increased by 8% Ig growth well above market

Continuing to invest in foundational tools for future growth

Successful transition of business model in China

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. 46 FY20: Strong Performance Across the Portfolio

1 1 20% growth in 21% growth in revenue YoY; revenue YoY; 3 Continued Growth in nearly all 2 launched markets growth in PID, CIDP 1 34% growth in revenue YoY and 2 clear SCIg market leader globally Transitioned New launches in EU, APAC and Canada; to GSP in China; 1 1 12% growth in 11% growth in revenue YoY revenue YoY ex-China

1 25% growth in revenue YoY; 1 2 1 12% growth in Market leadership in 20% growth in several key markets, including US, revenue YoY; Further Germany, Japan, Switzerland and Italy revenue YoY; approval of 2 penetration in US 4&5 gr vials

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. 2. Data on file 3. CSL Internal Reports 47 Targeted Protein Therapeutic Market

Albumin $4.1B Immunoglobulins $12.8B

Total Global Market Value Haemophilia ~$33.5B $11.9B

Specialty $4.7B

Source: Analyst Reports, Company Annual Reports, data on file; Haemophilia mkt includes Inhibitor mkt 48 Haemophilia +18% Coags Recombinant • Transformational product Sales increased by 8%1 • Leadership position in several key markets2

FY20 Sales • Approval of 21-day dosing in EU^, CH, JP & CA

• Patient retention strategies and ongoing switches in competitive environment

• New market launches 1 $1,122 PD Coags (3%) Coags PD

Plasma • Modest growth in HUMATE® ® Coagulation /HAEMATE (vWF) Factors • pdVIII competitive pressures Ig Haemophilia Specialty Albumin Other • MONONINE® to IDELVION® 1. Growth percentages shown at constant currency to remove the impact of exchange rate switches 1 movements, facilitating comparability of operational performance. 2. Data on file ^ Expanded label for dosing every 21 days for patients ≥12 years in age, depending on individual patient and efficacy (and jurisdiction) 49 AFSTYLA® Share of rFVIII Prophylaxis – Growing Steadily

AFSTYLA® rFVIII Prophylaxis Patient Share by Country 12% 11%

10% 9% 8%

6% 5% 5% Patient Share (%) 4% 4% 3%

2% 2% 2%

0% Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20

Germany Italy Japan Spain Switzerland US France Launched markets Avg.

Source: Data on file. Data only available for 7MM, BR, CH and AR through Q2’20; Launched markets include DE, IT, JP, ES, CH, US, and FR 7MM refers to US, DE, FR, IT, UK, ES & JP

50 IDELVION® Share of rFIX Prophylaxis – Significant Shares

® 70% IDELVION rFIX Prophylaxis Patient Share by Country

59% 60% 58% 57% 50% 44% 43% 40% 41%

30% 29%

Patient Share (%) 20%

10%

0% Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20

Germany Italy Japan Switzerland UK US Launched markets Avg.

Source: Data on file. Only available for 7MM, BR, CH and AR through Q2’20; Launched markets include DE, IT, JP, CH, UK, and US 7MM refers to US, DE, FR, IT, UK, ES & JP 51 Immunoglobulin Market

Global Ig Volume by Indication Market Dynamics

• Market growth above historical rates

• Growth in PID & CIDP

• Expanding usage for SID

• Market supply tightness pre-COVID-19

• COVID-19: Impact on plasma collection

• Shifting preference to SCIg and home administration

Source: Data on file

52 Immunoglobulins1 Sales increased by 22%2 *IVIg +16% • Increased disease awareness & FY20 Sales improved diagnosis in chronic therapies (PID & CIDP)

• Expansion of SID usage 2

• Launched PID/SID in Japan $4,014

• Market leader SCIg +34% • Increased preference for home administration

• Orphan exclusivity for CIDP in

the US 2 Ig Haemophilia Specialty Albumin Other • Continued CIDP launches

1. Excludes Ig hyperimmunes 2. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. * Includes Privigen®, Sandoglobulin®/ Carimune® and Intragam® 53 HIZENTRA®: Continued Strong Performance in SCIg Segment

80%

70% 62% 61% 61% 60% 60% 61% 59% 60% 60% 58% 57% 57% 58% 57% 60%

50%

40%

30%

20%

10% Share of SCIg Market (Volume) Total 7MM

0% Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20

Hizentra® (CSLB) Competitor A Competitor B Competitor C Competitor D Competitor E

Source: Data on file 7MM refers to US, DE, FR, IT, UK, ES & JP 54 CSL Behring Well-Positioned in CIDP

40%

35%

30%

25%

20%

15%

10% Patient Share (Total 7MM)

0% Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20

CSLB Competitor A Competitor B Competitor C Competitor D

Source: Data on file 7MM refers to US, DE, FR, IT, UK, ES & JP 55 Specialty Products Sales increased by 10%1

FY20 Sales

$1,697

Ig Haemophilia Specialty Albumin Other Peri-Operative Other Bleeding +10%1 Specialty +9%1

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. 56 HAEGARDA® Continues to Deliver in the US

HAEGARDA® reduced HAE attacks Prophylactic Almost 25% of by 95%* market** all new patients grew by 25%1 came from newest product Rescue medication launch1 use was reduced by >99%†‡1 Finished with most patients on HAEGARDA® since launch1

* Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA® vs placebo. † Median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA® vs placebo. ‡ The World Allergy Organization (WAO) guidelines for the management of HAE state that patients should have HAE rescue medication available at all times. ** Prophylactic non- steroids patient market 1. Data on file – represents US market only 57 Finished with Most Patients on HAEGARDA® Since Launch Patients

Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 HAEGARDA® Patients

Source: Data on file – represents US market only

58 KCENTRA® : OAC Market & KCENTRA® Utilization

US Clinical practice guidelines recommend KCENTRA® over FFP to reverse the effects of Warfarin*

Oral Anticoagulant (OAC) Market FY 19/20 Warfarin Urgent/Major Bleed Reversal Shares Kcentra® Utilization MAT CY Q4’19 Total: 6.9M Patients Total: 246M IUs

Other 80% 2% 70%

Warfarin/ 60% Product B Warfarin Coumadin 25% 50% Reversals 27% 34% 40% All Other 66% Product A 30% 46% 20%

10%

® Warfarin/ Coumadin Product A Product B Other KCENTRA FFP Others Warfarin Reversals All Other

Indicated for warfarin reversal. Not promoted in other areas Source: Data on file Source: Data on file + LRx Q4 2019 Source: CSL Internal data + Data on file+ LRx

All data represents US market only * Neurocritical Care Society, Society of Critical Care Medicine, American College of Cardiology, American College of Chest Physicians, American Society of Gastrointestinal Endoscopy, American College of Surgeons FFP – Fresh frozen plasma 59 Successful Transition of Business Model in China

Obtained the GSP1 license

Recruited and transferred all employees to GSP1 Entity

Completed in ~1 Year Implemented IT systems, interfaces & training

Developed and changed business processes for new affiliate

Established direct relationships with hospitals and key distributors

No impact to patient supply

1. Good Supply Practices (GSP)

60 Strong underlying demand Executing on strategies across the portfolio Commercial

Summary Balanced regional & key New products contributing market growth significantly to growth

Aligned therapeutic area Remain flexible and agile teams and strategy managing through COVID-19

61 Transplant Laurie Lee MD

Vice President, R&D Transplant

CSL Behring

62 Improve Outcomes for Transplant Recipients

Unmet needs in hematopoietic stem cell (HSCT) & solid organ transplantation

Before & During Transplantation After Transplantation

Lack of organs & optimally Inadequate long-term Need for less toxic post matched cells patient and graft survival transplantation regimens

• Shortage of available organs & • Graft-versus-Host Disease • Patients are at risk for organ discard (GvHD) is major risk to patient infection, malignancy and • Donor-recipient mismatch survival post-HSCT other comorbidities • Consequences of ischemia- • Antibody-Mediated Rejection reperfusion injury (AMR) is leading cause of long-term graft loss in kidney transplant recipients

Scientific focus: Anti-inflammatory & immune modulation

63 Three Ongoing Late-Phase Transplant Programs

Inadequate long-term patient and graft survival

Graft-versus-Host Disease (GvHD) Antibody-Mediated Rejection (AMR)

Phase III Phase II/III Phase III AAT (CSL964) AAT (CSL964) Clazakizumab (CSL300) treatment study in MODULAATE IMAGINE trial Interleukin 6 Blockade Modifying Antibody- collaboration with BMT prevention study Mediated Graft Injury and Estimated CTN (NHLBI/NCI) Glomerular Filtration Rate (eGFR) Decline 1 2 3

64 GvHD: Frequent Post-Transplantation Complication with High Morbidity and Mortality Clinical Manifestations

Up to 50% of patients develop GvHD after allogeneic HSCT despite current prophylactic regimens Skin GI Liver

Of those who develop acute GvHD, only 50% respond to treatment* (termed “steroid-refractory”)

Early Early Early Severity of acute GvHD varies: grades III and IV are the most severe

Mortality associated with grade III and grade IV one year after transplant is 75% Advanced Advanced Advanced and 95%, respectively** • Maculopapular rash • Upper GI: nausea, • Cholestatic jaundice vomiting • Hyperbilirubinemia • Lower GI: profuse watery diarrhoea; bloody diarrhoea or ileus * Ferrara, J. & Chaudry, M. (2018) Blood Adv. 2(22):3411-3417 ** Hill, L. et al., (2018) Ther Adv Hematol. 9(1):21-46 Source: Zeiser, R. & Blazar, B.R. (2017) N Engl J Med.377(22):2167-2179 65 Potential Mechanisms of AAT in GvHD

AAT Pre-Clinical Data 1 • Protease inhibition protects DAMPs 2 tissue Conditioning regimen, Tissue Activation and chemo-therapy damage Chemokines proliferation of or radiation Teff cells • Reduces pro-inflammatory PAMPs APC Naïve T cell 3 cytokine secretion

Cytokine storm: TNF- , IL-1 Acute GvHD IL-6, IL-32 • Decreases CD8+ effector AAT End-organ damage: α β Teff Skin, liver, gut IL-10 memory cells

AAT • Inhibits neutrophil migration AAT to sites of inflammation Treg IL-8 Promotion • Promotes release of Inhibition anti-inflammatory cytokine Neutrophil IL-10

Source: Adapted from Blazar, B. R., et al., (2012). Nat Rev Immunol 12(6): 443-458

66 Clinical Response to AAT in Patients with Steroid-Refractory acute GvHD (SR-aGvHD)

Overall Response Rate (ORR) Treg Fold Change Prospective, open label, Phase II study of i.v. AAT in SR-aGvHD* • 40 subjects, steroid-refractory acute GvHD • AAT twice weekly x 4 weeks at 60mg/kg • Overall response rate (ORR) (CR +

PR): at d28 = 65%; CR at d28=35% response % • Sustained response at d60 of 73%

Second smaller study (n=12) had consistent findings** Days after initiation of AAT

Figure 1. ORR. The percentage of patients who experienced an overall response (primary end point) as defined by the sum of patients with SR-aGvHD achieving complete response (CR) and partial * Magenau, J.M. et al., (2018) Blood. 131(12):1372-1379 response (PR) after initiation of AAT. ** Marcondes, A.M. et al., (2016) BBMT 22(9): 1596-1601 NR, nonresponder; Prog, progression. 67 AAT for GvHD Treatment Study: BMT CTN 1705 Collaboration opportunity with Blood and Marrow Transplant Clinical Trials Network BMT CTN (NHLBI/NCI)

AAT IV (120mg/kg) Twice weekly (x 8 doses) + CS Primary If Response: Acute GvHD Endpoint AAT or Randomization (1:1) Placebo (De Novo) Day 28 once weekly CR+PR (x 4 doses) Placebo IV (albumin) Twice weekly (x 8 doses) + CS

Enrollment Treatment Maintenance

BMT CTN (NHLBI/NCI) Phase III ongoing

68 MODULAATE AAT GvHD Prevention Phase II/III Study Part 1: Part 2: Dose Finding – Open Label Randomized Double Blind Placebo Controlled 3 ascending cohorts Cohort 4 (n=15) for each cohort Selected dose from Part 1 (n=260, 1:1; AAT: Placebo)

HSCT Adults & adolescents

AAT/Placebo

HSCT Day -5 -3 -1 0 7 14 21 28 35 42 49 56 63 70 77 84 91 100 120 150 180 270 365

MTX CNI Primary Endpoint: Phase II/III ongoing Proportion of acute Graft-versus-Host Disease-free survival at 180 days post-HSCT

69 Solid Organ Transplantation

Transplants by Organ Type (US - 2015)

Other 3%

Lung 7% Heart 9%

Liver Kidney 23% 58%

• >500,000 patients are living with a transplanted kidney*

* Scientific Registry of Transplant Recipients (SRTR) and European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 70 Antibody-Mediated Rejection (AMR) is a Leading Cause of Long-Term Graft Loss

Source: Sellarés et al., (2012) Am J Transplant. 12:388-99 Source: Halloran et al., (2015) J Am Soc Hephrol. 26:1711-1720

71 IL-6 Plays a Key Role in the Development of AMR

IL-6 Clazakizumab

Donor Specific Antibodies

IL-6 induces donor-specific antibodies (DSAs) leading to renal tissue damage

IL-6 Producing Plasma Cell Plasmablast Anti-inflammatory and immune modulatory Germinal Center IL-6 Clazakizumab effects of IL-6 blockade:

CD4+ Tfh Bcl-6+ CXCR5+ Naïve B-cell CD4+ Th17 cell • Reduces plasmablasts and proinflammatory T cells T naïve cell • Increases Treg cells HLA Class III • Decreases DSA production

• Reduces IL-6 production in activated ECs and DSA Activates IL-6 Normal EC Production in EC subsequent reduction in vasculopathy

Source: Adapted from Jordan, S. et al., (2017) Transplantation. 101 (1): 32-44

72 IMAGINE Clazakizumab for chronic AMR treatment study Treatment Phase: Day 1 to Week 260

Dosing with Clazakizumab 12.5 mg SC injection, Q4W (until graft loss or death): N=175 V2 V68 Follow-up Day 1 Wk 260 (monthly) V1 BL EOS assessments assessments Screening Day -42 to -1 Dosing with Placebo 1 mL SC injection, Q4W (until graft loss or death): N=l75

V2 V68 Follow-up Day 1 Wk 260 (monthly) BL EOS assessments assessments

Day 1 (BL) Last Dose 5 Months Randomization Week 256 (V67) After Last Dose 1st Dose of Study Drug

Week 52 • Interim analysis: 200 subjects • Subjects continue in study • Change from baseline in mean eGFR at Week 52 • Event driven final analysis • Expedited Approval • Time to All-Cause Graft Loss Phase III ongoing

73 Improve Outcomes for Transplant Recipients

Unmet needs in hematopoietic stem cell (HSCT) & solid organ transplantation

Before & During Transplantation After Transplantation

Lack of organs & optimally Inadequate long-term Need for less toxic post matched cells patient and graft survival transplantation regimens

• Shortage of available organs &  Graft-versus-Host Disease  Patients are at risk for organ discard (GvHD) is major risk to patient infection, malignancy and • Donor-recipient mismatch survival post-HSCT other comorbidities  • Consequences of ischemia- Antibody-Mediated Rejection reperfusion injury (AMR) is leading cause of long-term graft loss in kidney transplant recipients

Scientific focus: Anti-inflammatory & immune modulation

74 Summary William Mezzanotte MD

Executive Vice President, Head of Research and Development and CMO

CSL Behring

75 R&D Portfolio – October 2020

Registration/ Research Pre-Clinical Phase I Phase II Phase III Post-Registration

* Transaction with uniQure is subject to customary regulatory COVID-19 clearances before closing Hyperimmune Therapy

Immunology Haematology Respiratory Cardiovascular & Metabolic Transplant

Influenza Vaccines COVID Outlicensed Programs Partnered Projects

76 Significant Target Launch Dates

2019 2020 2021 2022 2023-2025

HIZENTRA® CIDP PRIVIGEN® PID FLUCELVAX® QUAD HAEGARDA® CSL510 Japan Japan 9yrs+ AU Japan Modified Fibrinogen

PRIVIGEN® CIDP IDELVION® UQ/CSL V451^ EtranaDez CSL112 Japan 21 Day Dosing (aCov2) Etranacogene ApoA-1 (ACS) dezaparvovec* AFLURIA® QIV FLUAD® QIV Garadacimab 6m+ (AUS) 65yrs+ US, EU Anti-FXIIa (HAE)

FLUCELVAX® QIV HIZENTRA® 9yrs+ EU (DM)

Clazakizumab Anti-IL-6 (AMR)

CSL964 AAT (GvHD Treatment)

Timelines shown by calendar year * Transaction with uniQure is subject to customary regulatory clearances before closing ^ Provisional Approval

Immunology Haematology Respiratory Cardiovascular & Metabolic Transplant

Influenza Vaccines COVID Outlicensed Programs Partnered Projects

77 R&D Portfolio Highlights – FY21 Transplant

• CSL964 (AAT) for prevention of GvHD - complete Part 1, adaptive phase of study, and advance to confirmatory Part 2

Immunology Respiratory Influenza Vaccines

• Garadacimab (Anti-FXIIa) initiate Phase III study • CSL311 (Anti-Beta Common) advance Phase I • FLUCELVAX® Quadrivalent EU & CA approvals in study in mild asthmatic patients 2+yrs indication • HAEGARDA® complete Phase III HAE study in Japan • Garadacimab (Anti-FXIIa) initiate Phase II ILD/IPF • FLUCELVAX® Quadrivalent US & CA submissions study 6mons+ indication • CSL324 (Anti-G-CSFR) initiate PK/Ethnicity study for SC formulation and inclusion of Japan • CSL787 (NebIg) initiate Phase I study • aQIVc (cell antigen + MF59®) initiate Phase II safety & immunogenicity study in adults 50+yrs

Cardiovascular and Haematology COVID Metabolic ® • COVID-19 Hyperimmune Therapy Phase III First • CSL112 (ApoA-1) Phase III study (AEGIS-II) • KCENTRA initiate Phase III study for treatment Patient In complete 2nd futility analysis (if applicable) of massive haemorrhage associated with severe traumatic injury • Garadacimab (Anti-FXIIa) complete Phase II • CSL346 (Anti-VEGF-B) initiate Phase II study for study DKD • EtranaDez* US Approval • UQ/CSL V451 Phase II/III First Patient In

* Transaction with uniQure is subject to customary regulatory clearances before closing 78 Panel Q&A Session